MD, PhD Executive Director,
Innovative Medicines Initiative
Michel Goldman, MD, PhD, is the Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI) since september 2009. With a budget of 2 billions € until 2017, IMI is a public-private partnership between the European Federation of Pharmaceutical Industries and Associations and the European Commission.
Professor of Immunology at the Université Libre de Bruxelles, Belgium, Michel Goldman was previously the Head of the Department of immunology-hematology-transfusion at the Hôpital Erasme (Brussels) and the Director of the Institute for Medical Immunology (Charleroi).
Michel Goldman has served the European Research Council as a member of the Advisory panel on Immunology and Infectious Diseases and he was the coordinator of two large European projects on immunotoxicology and transplantation. In 2006, he was appointed as vice-president of the BioWin Health Cluster created by the government of Wallonia to foster partnerships between industry and academic institutions.
Michel Goldman's scientific achievements resulted in more than 400 articles in peer-reviewed journals and he was recognised as ISI Highly Cited Scientist in 2006 by the Thomson Institute for Scientific Information. In 2000 he received the Joseph Maisin Prize, a major award for clinical sciences delivered by the Fonds National de la Recherche Scientifique (Belgium) and he held in 2001 the Spinoza chair at the University of Amsterdam, the Netherlands. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II, France.
- New partnership opportunities in the health sector ( 1.84 MB)
The Innovative Medicines Initiative (IMI) supports public-private cooperation and open innovation in biomedical research. The first 15 research projects co-funded by IMI are ongoing and the next 9 project proposals are under evaluation. The response to the IMI Calls for proposals demonstrate an increasing interest and enthusiasm for this type of large-scale partnerships, involving large pharmaceutical companies, SME's, patient organisations, regulatory agencies, academia and other research organisation.
IMI receives € 1 billion funding from the European Commission's Seventh Framework programme. The member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA) will match this amount with at least equal in kind contributions (consisting of research related activities and resources).